Status:
COMPLETED
Evaluation of the Antipsychotic Efficacy of Cannabidiol in Acute Schizophrenic Psychosis
Lead Sponsor:
University of Cologne
Conditions:
Schizophrenia
Eligibility:
All Genders
18-65 years
Phase:
PHASE2
Brief Summary
A controlled, randomized study on the treatment of schizophrenic psychosis with cannabidiol, a phytocannabinoid is performed. This approach is based upon recent findings indicating that the human endo...
Eligibility Criteria
Inclusion
- Clinical diagnosis of schizophrenia or schizophreniform psychosis according to DSM-IV.
- BPRS score \>36 and BPRS psychosis cluster \> 12.
- Ability to provide written informed consent.
- Participants are required an adequate contraception.
Exclusion
- Any severe neurological or somatic disorder.
- Other psychiatric disorders including addictive disorders.
- Positive urine drug screening for any compound except benzodiazepines.
- No pregnancy or breast feeding.
Key Trial Info
Start Date :
October 1 2002
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
March 1 2008
Estimated Enrollment :
42 Patients enrolled
Trial Details
Trial ID
NCT00628290
Start Date
October 1 2002
End Date
March 1 2008
Last Update
March 18 2008
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Cologne, Dept. of Psychiatry and Psychotherapy
Cologne, North Rhine-Westphalia, Germany, 50924